Table 4.

Relationship between history of ever having experienced menopausal symptoms and breast cancer risk stratified by HT use, age at menopause, and body mass index

Ever had menopausal symptoms
Ductal (n = 494)Lobular (n = 307)Ductal-lobular (n = 187)
ORa (95% CI)P for interactionORa (95% CI)P for interactionORa (95% CI)P for interaction
Overall0.5 (0.3–0.7)b0.5 (0.3–0.8)b0.7 (0.4–1.2)
Recency of HT use
 Never users0.5 (0.3–0.9)b0.80.6 (0.3–1.3)0.50.7 (0.3–1.7)0.9
 Former users0.5 (0.3–0.7)b0.5 (0.3–0.9)b0.7 (0.4–1.3)
 Current estrogen only users0.5 (0.3–0.8)b0.5 (0.3–0.8)b0.7 (0.4–1.3)
 Current E + P users0.5 (0.2–0.9)b0.4 (0.2–0.9)†0.7 (0.3–1.9)
Age at first use of any type of menopausal HT (years)
 <450.3 (0.1–1.0)0.40.7 (0.1–3.7)0.70.5 (0.1–3.4)0.6
 45–540.4 (0.2–0.8)†0.6 (0.3–1.6)0.6 (0.2–1.9)
 ≥550.5 (0.3–0.8)b0.6 (0.3–0.9)b0.8 (0.4–1.6)
Timing of first use of HT in relation to age at menopause
 Before menopause0.3 (0.1–1.7)0.60.5 (0.1–2.8)0.80.8 (0.1–5.8)0.9
 Same year as menopause0.4 (0.1–1.2)0.5 (0.1–1.6)0.8 (0.2–3.0)
 1–4 years after menopause0.5 (0.2–0.9)b0.5 (0.3–1.1)0.8 (0.4–1.9)
 ≥5 years after menopause0.6 (0.3–1.1)0.6 (0.3–1.2)0.8 (0.3–2.1)
Age at menopause
 <450.4 (0.1–1.2)0.60.7 (0.1–3.2)0.70.7 (0.1–4.1)0.8
 45–490.4 (0.2–0.9)b0.6 (0.2–1.7)0.7 (0.2–2.5)
 50–540.5 (0.3–0.8)b0.5 (0.3–1.0)0.8 (0.4–1.7)
 55+0.6 (0.3–0.9)b0.5 (0.3–0.8)b0.9 (0.4–1.8)
Years between age at menopause and reference age
 <80.6 (0.2–1.9)0.80.4 (0.1–1.4)0.70.8 (0.2–3.7)0.9
 8–140.5 (0.2–1.3)0.4 (0.2–1.0)0.7 (0.3–2.1)
 15–210.5 (0.3–0.9)0.4 (0.2–0.8)b0.7 (0.3–1.4)
 22+0.5 (0.3–0.8)b0.5 (0.3–0.9)b0.7 (0.3–1.4)
BMI, quartiles, kg/m2
 <23.40.7 (0.3–1.6)0.40.7 (0.2–2.0)0.61.7 (0.4–6.7)0.7
 23.4–26.40.6 (0.3–1.1)0.6 (0.3–1.2)1.2 (0.5–3.0)
 26.5–31.00.5 (0.3–0.8)b0.5 (0.3–0.9)b0.9 (0.5–1.6)
 31.1+0.4 (0.3–0.7)b0.5 (0.3–0.8)b0.6 (0.3–1.2)
  • aAll odds ratios (OR) are adjusted for age, year, duration of HT use, and the type of menopause.

  • bP < 0.05.